Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC
Liver Int
.
2023 Jan;43(1):258-259.
doi: 10.1111/liv.15482.
Epub 2022 Dec 5.
Authors
Ariel Jaffe
1
2
,
Tamar H Taddei
1
,
Edoardo G Giannini
3
,
Ysabel C Ilagan-Ying
1
,
Massimo Colombo
4
,
Mario Strazzabosco
1
2
Affiliations
1
Liver Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
2
Smilow Cancer Hospital and Liver Cancer Program, New Haven, Connecticut, USA.
3
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
4
Liver Center, San Raffaele Hospital, Milan, Italy.
PMID:
36426717
DOI:
10.1111/liv.15482
No abstract available
Publication types
Letter
Comment
MeSH terms
Artificial Intelligence
Biomarkers, Tumor
Carcinoma, Hepatocellular* / therapy
Humans
Liver Neoplasms* / therapy
Prognosis
Substances
Biomarkers, Tumor